{"entity":{"id":"nqmd-cs","kind":"trial","name":"NQMD-CS (five-cancer methylation test in a screening population, Guangzhou)","aka":["NQMD-CS"],"tldr":"A Chinese study of about 1,250 people testing a blood test for lung, bowel, liver, stomach and gullet cancer in ordinary screening.","summary":"NQMD-CS (NCT07834268) is a single-arm interventional study sponsored by Fifth Affiliated Hospital of Guangzhou Medical University. It evaluates the feasibility of a cell-free DNA methylation test that gives a binary result and predicts tissue of origin for five cancers.\n\nThe registry record, read on 29 October 2026, gives its status as active, not recruiting, with 1,250 participants enrolled, a start on 2 July 2025 and primary completion expected in October 2026.","status":"active","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT07834268","url":"https://clinicaltrials.gov/study/NCT07834268"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07834268","phase":"not-applicable","setting":"Adults without symptoms recruited in the community in Guangzhou, given a cell-free DNA methylation test for five cancers with standard screening and one-year follow-up","sponsor":"Fifth Affiliated Hospital of Guangzhou Medical University","started":"2025-07-02","startedType":"actual","enrolled":1250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nqmd-cs/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}